Novavax is the first protein-based COVID-19 vaccine to be provisionally approved by the Therapeutic Goods Administration (TGA). It has been proven safe and effective in protecting against severe illness or death associated with COVID-19 infection, with clinical trial data showing a robust immune response providing around 90 per cent protection …